RecruitingPhase 3NCT06561386
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bristol-Myers Squibb
- Principal Investigator
- Bristol-Myers SquibbBristol-Myers Squibb
- Intervention
- Nivolumab(drug)
- Enrollment
- 1000 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2032
Study locations (30)
- Local Institution - 0487, Mobile, Alabama, United States
- Southern Arizona VA Health Care System, Tucson, Arizona, United States
- Local Institution - 0112, Los Angeles, California, United States
- University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento, California, United States
- San Francisco Oncology Associates, San Francisco, California, United States
- UCLA Hematology/Oncology - Santa Monica, Santa Monica, California, United States
- Local Institution - 0472, Westminster, Colorado, United States
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami, Florida, United States
- Memorial Hospital West, Pembroke Pines, Florida, United States
- Florida Cancer Specialists - North, St. Petersburg, Florida, United States
- Local Institution - 0477, Tamarac, Florida, United States
- Florida Cancer Specialists - East, West Palm Beach, Florida, United States
- Affiliated Oncologists, LLC, Chicago Ridge, Illinois, United States
- Cancer Center of Kansas, Wichita, Kansas, United States
- Saint Elizabeth Medical Center Edgewood, Edgewood, Kentucky, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06561386 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07224152NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung CancerM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05987956Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsHan Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- RECRUITINGPHASE2NCT07104630Pulmonary Rehabilitation in Advanced Lung Cancer SurvivorsCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGEARLY PHASE1NCT07274813A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsShanghai Henlius Biotech
- RECRUITINGPHASE1NCT07358806Study to Assess the Effect of OCT-598 in Patients With Advanced Solid TumorsOscotec Inc.
- RECRUITINGPHASE3NCT06686771Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerCanadian Cancer Trials Group
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →